Candel Therapeutics, Inc. Common Stock (CADL)
Business numbers score is below the middle; score for how it compares with the broader market is near the top of its range; and smart-money score is on the low side.
CADL scores higher than 70% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Candel Therapeutics, Inc. Common Stock (CADL) scores 51 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.65× 30-day average
- 52-week range
- 4.35 – 14.00
- Market cap
- $830.23M
- Earnings date
- 5 Nov 2026
- Volume
- 718,368
- Avg. volume (30d)
- 1,112,644
- Open
- 9.69
- Previous close
- 9.66
- Day's range (regular session)
- 9.59 – 9.95
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- -0.26
- P/E (TTM)
- —
- EPS (TTM)
- -1.41
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for CADL
- 4 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for CADL. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about CADL right now
Candel Therapeutics, Inc. Common Stock (CADL) currently scores 51/100 on the Market Census six-factor composite, at the Average score level. CADL is +2.90% on the day and -2.36% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in CADL's data roughly balance out right now. CADL's strongest factor is strength vs the market at 99/100 — a very strong read on how CADL has done next to the wider market. It describes what has happened, not what happens next. The weakest factor is company finances at 0/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See CADL in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent CADL news
Latest headlines that name Candel Therapeutics, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Candel Therapeutics to Present at the SITC 2026 Annual MeetingGlobeNewswire Inc.
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo
- Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICIYahoo
- Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.Benzinga
- Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate CancerYahoo
We hide 6 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to CADL’s 51, all within 1 point.
Sorted by closeness to CADL’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.